Skip to main content

The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma (STEM)

Completed · Not applicable · NCT04410146

Conditions: Subdural Hematoma, Chronic

At a glance

Research payments reported, 2025
$382,602
U.S. investigators named
20
Sites paid
21
Planned or actual enrollment
319

About the trial

Sponsor
Balt USA
Tested
SQUID Embolization (device), SQUID Embolization and Surgical Evacuation (device), Surgical Evacuation (procedure), Standard Medical Management (other)
Dates
Started 2020-11-01; completion 2024-05-23
Results posted
Yes

STEM Study is a pivotal, international, multi-center, prospective, randomized (1:1) controlled trial designed to provide an assessment of the safety and effectiveness of Middle Meningeal Artery (MMA) embolization with SQUID for the management of Chronic Subdural Hematoma (cSDH)

From ClinicalTrials.gov, last updated 2026-06-04. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Balt USA, LLC reported $382,602 in research payments for this study in 2025 (75 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.